• Novo Nordisk reported improved liver markers with Wegovy 2.4 mg versus placebo in adults with MASH and liver scarring.
• The post hoc phase 3 ESSENCE analysis covered 106 adults with BMI below 27 kg/m², showing improvements at 72 weeks.
• Results showed reduced liver injury, disease activity and fibrosis markers; findings were presented at The Liver Meeting 2026 in Denver.
• The exploratory findings supplement biopsy-based results in a population that may be overlooked because MASH is often associated with obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.